From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

PZ Cussons – should I mope about a YTD unchanged share price?

By Chris Bailey | Wednesday 23 September 2020


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Only a week or so until the start of October and the formal start of the fourth quarter of a certainly different year. In the narrow commercial world of stock market investment, many of the thoughts in the institutional world will be about how year-to-date performance against both benchmarks and absolute terms is looking – and whether there are a few tweaks needed in the last few months of the year. For my personal pension fund such considerations should not really matter as – unless I fancy talking to myself – I don’t have to rock up early next year to talk to a much of dusty trustees, excitable intermediaries or comedy line managers about how well or badly my portfolios have done. However, all those years taking the institutional shilling continues to influence and – like the investment sad-o I am – on my monitoring spreadsheet I do have a year-to-date performance column. I have been a fan of PZ Cussons (PZC) for a while…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:32:43